TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)
The purpose of this study is to:
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@alnylam.com1-877-ALNYLAM
clinicaltrials@alnylam.com1-877-256-9526
Bunkyo C, 113-8519, Japan
Matsumoto-shi, 390-8621, Japan